SCHEMBL5129121

SCHEMBL5129121

Cc1csc2nc(-n3cncn3)nc(NCc3ccccc3)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.47
PDE10A Q9Y233 2/20 0.41
PDE5A O76074 5/20 0.39
TBXAS1 P24557 2/20 0.39
PDE3B Q13370 2/20 0.39
PDE3A Q14432 2/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
VCP P55072 2/20 0.38
LMNA P02545 2/20 0.38
RAB9A P51151 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
NOD2 Q9HC29 1/20 0.38
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5122264 0.90 ESR1 (0.48) ESR1PDE10ALMNARXFP1ALDH1A1
SCHEMBL5122240 0.85 ESR1 (0.48) ESR1PDE10A
SCHEMBL5121701 0.84 MAPT (0.43) ESR1PDE5APDE3BPDE3AALDH1A1
SCHEMBL5115335 0.84 ESR1 (0.48) ESR1PDE5ATBXAS1PDE3BPDE3A
SCHEMBL5124390 0.83 TNF (0.44) ESR1PDE5ARAB9A
SCHEMBL5116019 0.83 ALDH1A1 (0.47) ESR1PDE10APDE5ATBXAS1PDE3B
SCHEMBL5121170 0.82 TSHR (0.44) ESR1PDE5ALMNAALDH1A1CYP1A2
SCHEMBL5127699 0.82 CHRM4 (0.42) ESR1PDE10APDE5AALDH1A1ALOX15
SCHEMBL5122820 0.82 PDE5A (0.58) ESR1PDE5ATBXAS1PDE3BPDE3A
SCHEMBL5124544 0.81 PDE5A (0.39) ESR1PDE10APDE5ATBXAS1PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ESR1 2256/4885PDE10A 3363/4885PDE5A 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.